Share Twitter LinkedIn Facebook Email Eunice Wang, MD, talks about what we’ve learned about gilteritinib in FLT3-ITD mutated acute myeloid leukemia (AML) patients at the 2018 Annual Meeting.
Transforming AML Treatment: The Breakthrough Precision and Speed of Dr. Gabriel Mannis, MD on the Notable Platform Acute Myelogenous Leukemia 1 Min Read
Molecular Changes and Patient Stratification – Parrish Phimes, MD Acute Myelogenous Leukemia 2 Mins Read
